Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
2.160
-0.170 (-7.30%)
May 15, 2026, 4:00 PM EDT - Market closed
Context Therapeutics Employees
Context Therapeutics had 15 employees as of December 31, 2025. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change
3
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,681,795
Market Cap
198.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 3 | 25.00% |
| Sep 30, 2025 | 12 | 0 | - |
| Dec 31, 2024 | 12 | 7 | 140.00% |
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | - | - |
| Jun 30, 2021 | 2 | - | - |
| Mar 31, 2021 | 2 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Innate Pharma | 174 |
| Fate Therapeutics | 161 |
| Nkarta | 108 |
| Keros Therapeutics | 78 |
| Precision BioSciences | 68 |
| Milestone Pharmaceuticals | 38 |
| Corbus Pharmaceuticals Holdings | 36 |
CNTX News
- 11 days ago - Context Therapeutics reports Q1 EPS (9c), consensus (12c) - TheFly
- 11 days ago - Context Therapeutics Reports First Quarter 2026 Operating and Financial Results - GlobeNewsWire
- 6 weeks ago - Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA - TheFly
- 6 weeks ago - Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - Context Therapeutics price target raised to $7 from $4 at Piper Sandler - TheFly
- 7 weeks ago - Context Therapeutics Reports Full Year 2025 Operating and Financial Results - GlobeNewsWire
- 2 months ago - Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 2 months ago - Context Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts